At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 96 enrolled
Drug / intervention
PD1drug
Likely dose
PD1 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study
In Brief
A Phase 2 clinical trial evaluating PD1 for Relapsed/Refractory Classical Hodgkin's Lymphoma. Completed, enrolled 96 participants across 1 site.
Detailed Summary
The study is to evaluate ORR, CR, PR DCR DOR PFS and safety of IBI308 in treatment of patients with Relapsed/Refractory Hodgkin's Lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedApr 2017
Primary CompletionSep 2019
Study CompletionNov 2019
TodayJul 2026
First PostedApr 14, 2017
Enrollment StartMar 30, 2017
Primary CompletionSep 12, 2019
Study CompletionNov 30, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.2 years ago
Interventions
PD1drug
IBI308 200mg/3 weeks